Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey.
Department of Radiation Oncology, Istanbul University of Institute of Oncology, Istanbul, Turkey.
J Chemother. 2023 Jul;35(4):343-347. doi: 10.1080/1120009X.2022.2104295. Epub 2022 Jul 27.
The goal of the research was to investigate if a combination of vincristine, irinotecan and temozolomide (VIT) could benefit adult patients with metastatic Ewing sarcoma who had already been heavily pretreated. Metastatic Ewing sarcoma patients had their data retrospectively analyzed. The patients' clinical, radiological and therapeutic data were recorded. Survival analyzes were performed with these data. The study enlisted the participation of sixteen patients. The average age was 25 years old (range: 20-42). The lung was the most prevalent metastatic location (81.3%). Patients had received at least two distinct chemotherapy combinations (87.5%) and palliative radiotherapy (37.5%) before receiving the (VIT) combination. The Median progression-free survival time was found as 3.4 (95% CI, 1.8-4.9) months. Five patients (31.3%) experienced a partial response, while the remaining patients (68.7%) had progressing disease. Thirteen individuals (81.3%) had grade 1-2 adverse events, whereas five (31.3%) had grade 3-4 adverse events. Hematological complications were the most common side effects (87.5%). Median overall survival was calculated as 5.6 (95% CI, 3.6-7.5) months in the patients after the beginning of VIT regimen. We demonstrated the efficacy of the VIT regimen in adult patients with metastatic Ewing sarcoma in this research. In these extensively pretreated patients, toxicities were a concern. Metastatic Ewing sarcoma patients have few treatment choices. In patients who have had a good performance status, VIT regimen may be considered for disease control.
本研究旨在探讨长春新碱、伊立替康和替莫唑胺（VIT）联合方案是否对已接受过大量预处理的转移性尤文肉瘤成人患者有益。回顾性分析转移性尤文肉瘤患者的数据。记录患者的临床、影像学和治疗数据。对这些数据进行生存分析。该研究纳入了 16 名患者。平均年龄为 25 岁（范围：20-42 岁）。肺部是最常见的转移部位（81.3%）。在接受（VIT）联合方案之前，患者至少接受了两种不同的化疗联合方案（87.5%）和姑息性放疗（37.5%）。中位无进展生存期为 3.4 个月（95%CI，1.8-4.9）。5 名患者（31.3%）出现部分缓解，其余患者（68.7%）疾病进展。13 名患者（81.3%）发生 1-2 级不良事件，5 名患者（31.3%）发生 3-4 级不良事件。血液学并发症最常见（87.5%）。VIT 方案开始后，患者的中位总生存期为 5.6 个月（95%CI，3.6-7.5）。本研究证明了 VIT 方案在转移性尤文肉瘤成人患者中的疗效。在这些经过大量预处理的患者中，毒性是一个问题。转移性尤文肉瘤患者的治疗选择有限。在一般状况良好的患者中，可考虑使用 VIT 方案控制疾病。
